Triggering with HCG or GnRH agonist in GnRH antagonist treated oocyte donation cycles: a randomised clinical trial

References

• Lutjen P, Trounson A, Leeton J, Findlay J, Wood C, Renou P. The establishment and maintenance of pregnancy using in vitro fertilization and embryo donation in a patient with primary ovarian failure. Nature 1984; 307: 174–175
   PubMed Web of Science ®Google Scholar
• Chang P, Kenley S, Burns T, Denton G, Currie K, DeVane G, O'Dea L. Recombinant human chorionic gonadotropin (rhCG) in assisted reproductive technology: results of a clinical trial comparing two doses of rhCG (Ovidrel) to urinary hCG (Profasi) for induction of final follicular maturation in in vitro fertilization-embryo transfer. Fertil Steril 2001; 76: 67–74
   PubMed Web of Science ®Google Scholar
• Fauser B C, de Jong D, Olivennes F, Wramsby H, Tay C, Itskovitz-Eldor J, van Hooren H G. Endocrine profiles after triggering of final oocyte maturation with GnRH agonist after cotreatment with the GnRH antagonist ganirelix during ovarian hyperstimulation for in vitro fertilization. J Clin Endocrinol Metab 2002; 87: 709–715
   PubMed Web of Science ®Google Scholar
• Itskovitz J, Boldes R, Levron J, Erlik Y, Kahana L, Brandes J M. Induction of preovulatory luteinizing hormone surge and prevention of ovarian hyperstimulation syndrome by gonadotropin-releasing hormone agonist. Fertil Steril 1991; 56: 213–220
   PubMed Web of Science ®Google Scholar
• Delvigne A, Rozenberg S. Epidemiology and prevention of ovarian hyperstimulation syndrome (OHSS): a review. Hum Reprod Update 2002; 8: 559–577
   PubMed Web of Science ®Google Scholar
• Olivennes F, Fanchin R, Bouchard P, Taieb J, Frydman R. Triggering of ovulation by a gonadotropin-releasing hormone (GnRH) agonist in patients pretreated with a GnRH antagonist. Fertil Steril 1996; 66: 151–153
   PubMed Web of Science ®Google Scholar
• Humaidan P, Bredkjaer H E, Bungum L, Bungum M, Grondahl M L, Westergaard L, Andersen C Y. GnRH agonist (buserelin) or hCG for ovulation induction in GnRH antagonist IVF/ICSI cycles: a prospective randomized study. Hum Reprod 2005; 20: 1213–1220
   PubMed Web of Science ®Google Scholar
• Kolibianakis E M, Schultze-Mosgau A, Schroer A, van Steirteghem A, Devroey P, Diedrich K, Griesinger G. A lower ongoing pregnancy rate can be expected when GnRH agonist is used for triggering final oocyte maturation instead of HCG in patients undergoing IVF with GnRH antagonists. Hum Reprod 2005; 20: 2887–2892
   PubMed Web of Science ®Google Scholar
• Shapiro B S, Daneshmand S T, Garner F C, Aguirre M, Ross R. Comparison of human chorionic gonadotropin and gonadotropin-releasing hormone agonist for final oocyte maturation in oocyte donor cycles. Fertil Steril 2007; 88: 237–239
   PubMed Web of Science ®Google Scholar
• Acevedo B, Gomez-Palomares J L, Ricciarelli E, Hernandez E R. Triggering ovulation with gonadotropin-releasing hormone agonists does not compromise embryo implantation rates. Fertil Steril 2006; 86: 1682–1687
   PubMed Web of Science ®Google Scholar
• Navot D, Bergh P A, Laufer N. Ovarian hyperstimulation syndrome in novel reproductive technologies: prevention and treatment. Fertil Steril 1992; 58: 249–261
   PubMed Web of Science ®Google Scholar
• Coroleu B, Barri P N, Carreras O, Martinez F, Parriego M, Hereter L, Parera N, Veiga A, Balasch J. The influence of the depth of embryo replacement into the uterine cavity on implantation rates after IVF: a controlled, ultrasound-guided study. Hum Reprod 2002; 17: 341–346
   PubMed Web of Science ®Google Scholar
• Daya S. Pitfalls in the design and analysis of efficacy trials in subfertility. Hum Reprod 2003; 18: 1005–1009
   PubMed Web of Science ®Google Scholar
• Bodri D, Vernaeve V, Guillen J J, Vidal R, Figueras F, Coll O. Comparison between a GnRH antagonist and a GnRH agonist flare-up protocol in oocyte donors: a randomized clinical trial. Hum Reprod 2006; 21: 2246–2251
   PubMed Web of Science ®Google Scholar
• Nakano R, Mizuno T, Kotsuji F, Katayama K, Wshio M, Tojo S. “Triggering” of ovulation after infusion of synthetic luteinizing hormone releasing factor (LRF). Acta Obstet Gynecol Scand 1973; 52: 269–272
   PubMed Web of Science ®Google Scholar
• Babayof R, Margalioth E J, Huleihel M, Amash A, Zylber-Haran E, Gal M, Brooks B, Mimoni T, Eldar-Geva T. Serum inhibin A, VEGF and TNFalpha levels after triggering oocyte maturation with GnRH agonist compared with HCG in women with polycystic ovaries undergoing IVF treatment: a prospective randomized trial. Hum Reprod 2006; 21: 1260–1265
   PubMed Web of Science ®Google Scholar
• Beckers N G, Macklon N S, Eijkemans M J, Ludwig M, Felberbaum R E, Diedrich K, Bustion S, Loumaye E, Fauser B C. Nonsupplemented luteal phase characteristics after the administration of recombinant human chorionic gonadotropin, recombinant luteinizing hormone, or gonadotropin-releasing hormone (GnRH) agonist to induce final oocyte maturation in in vitro fertilization patients after ovarian stimulation with recombinant follicle-stimulating hormone and GnRH antagonist cotreatment. J Clin Endocrinol Metab 2003; 88: 4186–4192
   PubMed Web of Science ®Google Scholar
• Kol S. Luteolysis induced by a gonadotropin-releasing hormone agonist is the key to prevention of ovarian hyperstimulation syndrome. Fertil Steril 2004; 81: 1–5
   PubMed Web of Science ®Google Scholar
• Imoedemhe D A, Sigue A B, Pacpaco E L, Olazo A B. Stimulation of endogenous surge of luteinizing hormone with gonadotropin-releasing hormone analog after ovarian stimulation for in vitro fertilization. Fertil Steril 1991; 55: 328–332
   PubMed Web of Science ®Google Scholar
• Emperaire J C, Ruffie A. Triggering ovulation with endogenous luteinizing hormone may prevent the ovarian hyperstimulation syndrome. Hum Reprod 1991; 6: 506–510
   PubMed Web of Science ®Google Scholar
• Engmann L, DiLuigi A, Schmidt D, Nulsen J, Maier D, Benadiva C. The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective randomized controlled study. Fertil Steril 2008; 89: 84–91
   PubMed Web of Science ®Google Scholar
• Imoedemhe D A, Chan R C, Sigue A B, Pacpaco E L, Olazo A B. A new approach to the management of patients at risk of ovarian hyperstimulation in an in-vitro fertilization programme. Hum Reprod 1991; 6: 1088–1091
   PubMed Web of Science ®Google Scholar
• Kol S, Solt I. GnRH agonist for triggering final oocyte maturation in patients at risk of ovarian hyperstimulation syndrome: still a controversy. J Assist Reprod Genet 2008; 25: 63–66
   PubMed Web of Science ®Google Scholar
• Pirard C, Donnez J, Loumaye E. GnRH agonist as luteal phase support in assisted reproduction technique cycles: results of a pilot study. Hum Reprod 2006; 21: 1894–1900
   PubMed Web of Science ®Google Scholar
• Humaidan P, Bungum L, Bungum M, Yding Andersen C. Rescue of corpus luteum function with peri-ovulatory HCG supplementation in IVF/ICSI GnRH antagonist cycles in which ovulation was triggered with a GnRH agonist: a pilot study. Reprod Biomed Online 2006; 13: 173–178
   PubMed Web of Science ®Google Scholar
• Shapiro B S, Daneshmand S T, Garner F C, Aguirre M, Thomas S. Gonadotropin-releasing hormone agonist combined with a reduced dose of human chorionic gonadotropin for final oocyte maturation in fresh autologous cycles of in vitro fertilization. Fertil Steril 2008; 90: 231–233
   PubMed Web of Science ®Google Scholar
• Griesinger G, Kolibianakis E M, Papanikolaou E G, Diedrich K, Van Steirteghem A, Devroey P, Ejdrup Bredkjaer H, Humaidan P. Triggering of final oocyte maturation with gonadotropin-releasing hormone agonist or human chorionic gonadotropin. Live birth after frozen-thawed embryo replacement cycles. Fertil Steril 2007; 88: 616–621
   PubMed Web of Science ®Google Scholar
• Griesinger G, von Otte S, Schroer A, Ludwig A K, Diedrich K, Al-Hasani S, Schultze-Mosgau A. Elective cryopreservation of all pronuclear oocytes after GnRH agonist triggering of final oocyte maturation in patients at risk of developing OHSS: a prospective, observational proof-of-concept study. Hum Reprod 2007; 22: 1348–1352
   PubMed Web of Science ®Google Scholar
• Bodri D, Guillen J J, Galindo A, Mataro D, Pujol A, Coll O. Triggering with human chorionic gonadotropin or a gonadotropin-releasing hormone agonist in gonadotropin-releasing hormone antagonist-treated oocyte donor cycles: findings of a large retrospective cohort study. Fertil Steril, in press
   Web of Science ®Google Scholar
• Melo M AB, Busso C E, Alama P, Meseguer M, Garrido N, Remohi J. A randomized, prospective, assessor-blind, parallel groups, comparing GnRHa vs. rhCG as a trigger final oocyte maturation in GnRH antagonist IVF/ICSI cycles. Fertil Steril 2007; 88: S43
   Web of Science ®Google Scholar